SITE011-0347

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2023-04-07

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-05-01 (study day 6); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-05-02 (study day 7); relationship: not assessed

severe assessed

Grade 3 Rash — outcome: RECOVERED/RESOLVED; onset 2023-05-17 (study day 22); relationship: not assessed

moderate assessed

Grade 2 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 33); relationship: not assessed

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-06-04 (study day 40); relationship: not assessed

Data queries

No data queries.